The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel

Abstract

ABSTRACTBackground: The European Society for Medical Oncology published in 2015 its Magnitude of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. Our objective was to evaluate the association between Israel’s national reimbursement decisions regarding novel cancer drugs, prior to the availability of ESMO-MCBS, and the later published ESMO-MCBS scores.Research design and methods: ESMO-MCBS scores were obtained retrospectively for the cancer drugs that were candidates for reimbursement in Israel in 2013–2015 and were categorized to ‘highest benefit’ (ESMO-MCBS 4–5 or A) ‘medium benefit’ (3 or B) and ‘lowest benefit’ (0–2 or C). The reimbursement decisions were accessed and compared with the categorized ESMO scores.Results: ESMO-MCBS score was available for 19/22 drugs approved for reimbursement and 15/16 non-approved drugs. 58% of the approved drugs gained a ‘highest benefit’ score and 37% were ‘medium benefit’. 87% of the non-approved drugs had ‘lowest benefit’ scores. Median score for approved drugs was 4 vs. 1 for the non-approved (p < 0.05).Conclusions: The Israeli decisions regarding reimbursement of novel cancer drugs, demonstrated concordance with ESMO-MCBS scores. Incorporation of ESMO-MCBS data in reimbursement deliberations could assist in framing the appropriate use of the limited resources to deliver effective and affordable cancer care.